BergenBio Fundamentale Forhold (BGBIO)

Boms · desember 13, 2021, 2:45pm

Virker jo lovende dette:

Gj.sn. alder på pasientene er 76 år, så man kan neppe forvente større økning i respons/overlevelse enn dette.

Realize_1 · desember 13, 2021, 2:56pm

Ser på posteren at «survival data continues to mature».

TekBot · desember 14, 2021, 6:44am

BerGenBio to present at DNB Nordic Healthcare Conference 2021

Bergen, Norway, 14 December 2021- BerGenBio ASA (OSE:BGBIO), BerGenBio ASA (OSE:
BGBIO), a clinical-stage biopharmaceutical company developing novel, selective
AXL kinase inhibitors for severe unmet medical needs, is pleased to announce
…

Vis børsmeldingen

that it will be presenting at the 12th DNB Nordic Healthcare Conference on 16th
December 2021.

The presentation will take place from 11:35 CET and will be made available on
the Company website: www.bergenbio.com/investors/presentations/

-End-

Contacts

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone

Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer and COVID
-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is
undergoing phase I clinical testing. In parallel, BerGenBio is developing
companion diagnostic tests to potentially identify patient populations most
likely to benefit from AXL inhibition. This is expected to facilitate more
efficient registration trials supporting a precision medicine-based
commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Suchrisks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

alfred_e_neuman · desember 14, 2021, 10:53pm

AXL receptor is required for Zika virus strain MR-766 infection in human glioblastoma cell lines

Published: November 10, 2021

https://www.cell.com/molecular-therapy-family/oncolytics/fulltext/S2372-7705(21)00150-9 (DOI)

Recent reports have shown that Zika virus (ZIKV) has oncolytic potential against human glioblastoma (GBM); however, the mechanisms underlying its tropism and cell entry are not completely understood. The receptor tyrosine kinase AXL has been identified as an entry receptor for ZIKV in a cell-type-specific manner. Interestingly, AXL is frequently overexpressed in GBM patients. Using commercially available GBM cell lines, we first show that cells expressing AXL are permissive for ZIKV infection, while cells that do not express AXL are not.

Furthermore, inhibition of AXL kinase using R428 and antibody blockade of AXL receptor strongly attenuated virus entry in GBM cell lines. Additionally, CRISPR knockout of the AXL gene in GBM cell lines completely abolished ZIKV infection, significantly inhibited viral replication, and significantly reduced apoptosis compared with parental lines. Lastly, introduction of AXL receptor into non-expressing cell lines renders the cells susceptible to ZIKV infection.

Together, these findings demonstrate that ZIKV entry into GBM cells in vitro is mediated by the AXL receptor and that following cell entry, productive infection is cytotoxic. Thus, ZIKV is a potential oncolytic virus for GBM.

(Bemcentinib, also known as BGB324 or R428)

Ekornet · desember 15, 2021, 6:07pm

Blir spennende å få resultatene fra Glioblastom studien i USA, tipper mot slutten av 2022.

TekBot · desember 16, 2021, 6:31am

BerGenBio announces exclusive in-license of key intellectual property rights from UT Southwestern Medical Center

In-Licensing further strengthens intellectual property estate for the treatment
of Non-Small Cell Cancer (NSCLC) patients with STK11 mutations

…

Vis børsmeldingen

Bergen, Norway, 16 December 2021- BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL inhibitors for severe
unmet medical needs, announced today the licensing of certain intellectual
property from the UT Southwestern Medical Center. The exclusive license to
intellectual property generated by researchers at UT Southwestern Medical Center
supports the Company’s existing IP position underlying use of AXL inhibitors,
including its lead product candidate bemcentinib, for the treatment of patients
harboring STK11 mutations in NSCLC. No financial terms have been disclosed.

The STK11 mutation is observed in up to 20% of NSCLC patients. STK11 is an
important tumor suppressor gene associated with a poor prognosis in NSCLC
patients and which has been reported in some studies to confer resistance to
immune checkpoint inhibitors.

Researchers at the UT Southwestern Medical Center and BerGenBio recently
presented data at the 2021 Society for Immunotherapy of Cancer (SITC) 36thAnnual
Meeting exploring why patients harboring a mutation to the STK11 gene may not
respond to anti-PD1 therapy, a commonly used treatment in first line NSCLC
patients. Preclinical research further indicated that the addition of the
selective AXL inhibitor bemcentinib restored the activity of anti-PD1 treatment
in relevant lung cancer models

Martin Olin, Chief Executive Officer at BerGenBio, commented: “The license
agreement with UT Southwestern Medical Center complements our existing
intellectual property filings in this important patient population which appears
to poorly respond to anti-PD1 therapy. We will continue to explore how this
target group might be addressed by the combination of bemcentinib and an immune
checkpoint inhibitor.”

-End-

Contacts

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone

Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer and COVID
-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is
undergoing phase I clinical testing. In parallel, BerGenBio is developing
companion diagnostic tests to potentially identify patient populations most
likely to benefit from AXL inhibition. This is expected to facilitate more
efficient registration trials supporting a precision medicine-based
commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Suchrisks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

TekBot · desember 16, 2021, 2:01pm

BerGenBio ASA: Notice of Extraordinary General Meeting

Bergen, Norway, 16 December 2021 - Notice is hereby given that an Extraordinary
General Meeting in BerGenBio ASA (OSE:BGBIO) will be held on 6 January 2022 at
10:00 hours (CET).
…

Vis børsmeldingen

The notice, registration form and power of attorney are attached to this

release. The notice will be sent to all registered shareholders and is
available at https://www.bergenbio.com/investors/general-
meetings/ (General Meetings - BerGenBio)

All shareholders are encouraged to exercise their shareholder rights. Due to the
ongoing corona virus pandemic, the Board encourages shareholders not to attend
the general meeting in person, but rather to make use of the ability to vote by
proxy.The proxy form is attached to this release and available on the Company’s
website: General Meetings - BerGenBio

The following items are on the agenda: (i) Election of new Chair of the Board of
Directors and changes to the board (ii) Remuneration to the chair of the board.

We encourage all shareholders to register as electronical user in VPS to save
environment impact.

-Ends-

Contacts

Martin Olin, CEO, BerGenBio ASA
ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer and COVID
-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is
undergoing phase I clinical testing. In parallel, BerGenBio is developing
companion diagnostic tests to potentially identify patient populations most
likely to benefit from AXL inhibition. This is expected to facilitate more
efficient registration trials supporting a precision medicine-based
commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Suchrisks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

TekBot · desember 17, 2021, 12:44pm

Financial calendar

Tekspert · januar 1, 2022, 10:00am

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

@anon28800809 (741 likes)

@Roc (303 likes)

@Hayen (127 likes)

Resten av topp 10:

@Scrivener (85 likes)
@vcp (85 likes)
@Direkte (73 likes)
@Multiple (67 likes)
@Realize_1 (66 likes)
@PankPinter (58 likes)
@Ekornet (53 likes)

Gratulerer!

TekBot · januar 6, 2022, 7:58am

BerGenBio - Mandatory notification of trade by Primary Insiders

vcp · januar 6, 2022, 9:07am

Må mangle en desimal der, skal markedet få troen på at CEO, har overbevisningen.

Walk the talk.

Men riktignok bedre enn Godfrey.

Zuba · januar 6, 2022, 9:10am

Sign on fee det der. så det er du og jeg som har kjøpt til han sånn i grove trekk:joy:

vcp · januar 6, 2022, 9:12am

Ikke verd vatten då

TekBot · januar 6, 2022, 9:29am

BerGenBio ASA: Extraordinary General Meeting held

Bergen, Norway, 6 January 2022 - BerGenBio ASA (OSE:BGBIO) announces that an
extraordinary general meeting in the Company was held on 6 January 2022.

…

Vis børsmeldingen

All proposals were resolved as presented in the notice convening the
extraordinary general meeting distributed on 16 December 2022, as further set
out in the minutes from the extraordinary general meeting attached hereto and
available at https://www.bergenbio.com/investors/general-
meetings/ (General Meetings - BerGenBio)

-Ends-

For further information, please contact:

Martin Olin, CEO, BerGenBio ASA
ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

TekBot · januar 6, 2022, 9:31am

BERGENBIO APPOINTS ANDERS TULLGREN AS CHAIRMAN OF BOARD

Bergen, Norway, 6 January 2022- BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, announces today the appointment of Anders Tullgren to
…

Vis børsmeldingen

succeed Sveinung Hole as Chairman of the Board of Directors, effective today.
Sveinung Hole has been Chairman of the Board since March 2019 and will continue
to serve as a Board Member.

Anders Tullgren has over 35 years of global experience in both large
pharmaceutical and small/mid-size biotech environments, with senior leadership
roles in the United States, Germany, France, the United Kingdom, and the Nordic
region. He spent over 20 years at Bristol Myers Squibb, most recently as
President, Intercontinental Region at the firm, with responsibility across 30
countries, 5,000 employees and a turnover of over 2.7 billion USD. Anders has in
his career worked with several oncology products and was leading the successful
launch of BMS immuno-oncology portfolio in the intercontinental region.

Anders is an experienced non-executive director with current Board and Chair
positions at Branding Science Ltd (UK), Xbrane Biopharma AB (Sweden), Farmalisto
(Panama) and Dizlin Pharmaceuticals AB (Sweden). He holds an MSc in
Pharmaceutical Studies from Uppsala University (Sweden) and a Diploma in
Marketing & Business Administration from MIS (Sweden).

Martin Olin, Chief Executive Officer of BerGenBio, commented: “We’re delighted
to welcome Anders Tullgren as Chairman. Anders’ experience and deep knowledge of
development, commercialization and growth planning is highly valuable in our
journey to provide novel therapeutic modalities to treat severe diseases. I’d
like to take this opportunity to thank Sveinung for his excellent leadership of
the Board during the past few years, which have seen a number of important
milestones as we progress our clinical trials.”

On his appointment as Chairman of the Board, Anders Tullgren said: “It is an
honor to have the opportunity to take on the role of Chairman and to work within
an incredible company and alongside a strong leadership team. I look forward to
supporting BerGenBio as it advances the progression of its lead candidate,
bemcentinib, and working closely with Martin, Sveinung and the rest of the
Board.”

-End-

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer and COVID
-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is
undergoing phase I clinical testing. In parallel, BerGenBio is developing a
potential companion diagnostic test to identify patient populations most likely
to benefit from AXL inhibition: this is expected to facilitate more efficient
registration trials supporting a precision medicine-based commercialisation
strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit? www.bergenbio.com

Contacts

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone

Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

Troso · januar 6, 2022, 9:51am

Det var vel ny styreleder som skulle få sign-on bonus for aksjekjøp? 25000 aksjer. Så CEO’s kjøp er vel fra egen lomme??

Aristo78 · januar 6, 2022, 9:55am

Ja, ganske sikker på at du har rett i det.

TekBot · januar 7, 2022, 8:04am

BERGENBIO - Mandatory notification of trade by Primary Insider

drdr · januar 7, 2022, 8:22am

Og snart kommer ny melding også om allerede annonserte 25k innsidehandel av Anders Tullgren!

TekBot · januar 7, 2022, 4:51pm